Table 1.
Patient characteristics of stroke and control patients for HMGB1 blood analysis
| Controls | Stroke patients | p | |
|---|---|---|---|
| Total patients per group | 20 | 104 | |
| Age (years) | 69.3 ± 9.2 | 73.2 ± 10.4 | 0.241 |
| NIHSS on admission | 0 | 11.7 ± 6.4 | — |
| Median stroke volume (ml) | NA | 29.4 | — |
| Laterality (right/left) | NA | 53/51 | — |
| Blood samples (n) obtained within 24 h after symptom onset | NA | 104 | — |
| Blood samples (n) obtained within 72 h after symptom onset | NA | 153a | — |
| Mean time: symptom onset to first blood sampling (hours) | NA | 10.7 ± 5.2 | — |
| Comorbidities | |||
| Hypercholesterolemia | 6 (30%) | 27 (26%) | 0.998 |
| Arterial hypertension | 17 (85%) | 72 (69%) | 0.151 |
| Diabetes | 7 (35%) | 30 (29%) | 0.581 |
| Premedication | |||
| β-AR blocker | 7 (35%) | 39 (38%) | 0.832 |
| Oral anticoagulationb | 4 (20%) | 17 (16%) | 0.689 |
| Antithromboticsc | 8 (27%) | 17 (24%) | 0.167 |
| Sympathicoactive medicationd | 3 (15%) | 7 (7%) | 0.069 |
a Forty-nine patients were measured twice (at hospital admission and at day 3 after stroke onset).
b Phenprocoumon, rivaroxaban.
c Aspirin, aspirin + dipyridamole, clopidogrel.
d Clonidin, oxybutinin, inhalable β2-AR agonists, doxazosin, terazosin.